Latest Content

Clinicians of color can experience higher rates of vicarious trauma when treating patients with cancer.

Nursing ethics expert Katherine Brown-Saltzman, MA, RN, shares insights on how to manage difficult ethical issues when treating patients with cancer.

Expert advice for administering and monitoring liso-cel in patients with follicular lymphoma.

The microbiota-based therapy MaaT013 showed promising efficacy and manageable safety in those with acute GVHD with gastrointestinal involvement.

Look back at the top 5 updates for oncology nurses and advanced practices providers published in 2025.

Patient K.C. transitions from high-risk care to invasive mammary carcinoma treatment under the care and support of a breast cancer advanced practice provider.

Age and having children were found to affect whether premenopausal women with breast cancer opted for fertility preservation.

Risvutatug rezetecan, an antibody-drug conjugate was granted FDA orphan drug designation for use in patients with small cell lung cancer.

Melinda Mayorga, RN, MSN, CNS, AGCNS-BC, OCN, discusses end-of-life care from a multidisciplinary perspective.

Subcutaneous mosunetuzumab wins FDA accelerated approval in patients with R/R follicular lymphoma following 2 or more lines of systemic therapy.

Breast cancer survivors improved cognitive outcomes with both real and sham acupuncture, but real acupuncture showed greater gains.

As CAR T-cell therapy expands to solid tumors, oncology nurses play a key role in monitoring, educating, and supporting patients.

Giredestrant displayed a safety profile consistent with prior findings and had a lower rate of discontinuation compared with standard endocrine therapy.